These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. Witchel SF; Oberfield SE; Peña AS J Endocr Soc; 2019 Aug; 3(8):1545-1573. PubMed ID: 31384717 [TBL] [Abstract][Full Text] [Related]
24. Polycystic Ovary Syndrome and Gender Identity. Liu M; Murthi S; Poretsky L Yale J Biol Med; 2020 Sep; 93(4):529-537. PubMed ID: 33005117 [TBL] [Abstract][Full Text] [Related]
25. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2. Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ; Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102 [TBL] [Abstract][Full Text] [Related]
26. Polycystic Ovary Syndrome in Adolescents. Witchel SF; Roumimper H; Oberfield S Endocrinol Metab Clin North Am; 2016 Jun; 45(2):329-44. PubMed ID: 27241968 [TBL] [Abstract][Full Text] [Related]
27. Management of polycystic ovary syndrome in childhood and adolescence. Ojaniemi M; Tapanainen P; Morin-Papunen L Horm Res Paediatr; 2010; 74(5):372-5. PubMed ID: 20861609 [TBL] [Abstract][Full Text] [Related]
28. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633 [TBL] [Abstract][Full Text] [Related]
29. Insulin-sensitisers in the treatment of polycystic ovary syndrome. Teede HJ; Meyer C; Norman RJ Expert Opin Pharmacother; 2005 Nov; 6(14):2419-27. PubMed ID: 16259573 [TBL] [Abstract][Full Text] [Related]
33. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. Skiba MA; Bell RJ; Herbert D; Garcia AM; Islam RM; Davis SR Hum Reprod; 2021 May; 36(6):1611-1620. PubMed ID: 33846715 [TBL] [Abstract][Full Text] [Related]
34. In utero exposure to maternal stressful life events and risk of polycystic ovary syndrome in the offspring: The Raine Study. Koch T; Doherty DA; Dickinson JE; Juul A; Hart R; Bräuner EV; Hickey M Psychoneuroendocrinology; 2021 Mar; 125():105104. PubMed ID: 33352473 [TBL] [Abstract][Full Text] [Related]
35. Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome. O'Brien B; Dahiya R; Kimble R BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32276996 [TBL] [Abstract][Full Text] [Related]
36. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction. González F Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932 [TBL] [Abstract][Full Text] [Related]
37. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. Ibáñez L; de Zegher F J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917 [TBL] [Abstract][Full Text] [Related]